Die Prime Vector Technologies GmbH gibt eine Lizenzvereinbarung mit Boehringer Ingelheim bekannt, um Krebs-Impfstoff-Therapien der nächsten Generation voranzutreiben
Die Prime Vector Technologies GmbH (PVT), ein Biotechnologieunternehmen im klinischen Stadium, das sich auf die Entwicklung von Impfstoffen auf Basis viraler Vektoren konzentriert, gab heute bekannt, dass es eine Vereinbarung mit Boehringer Ingelheim über die Übertragung bestimmter Patente und die exklusive Lizenzierung seiner Orf-Virus-Plattform (ORFV) zur Entwicklung von Krebsimpfstoffen der nächsten Generation geschlossen hat. Die ORFV-Plattform von PVT ist als vielseitige virale Vektorplattform für den potenziellen Einsatz in den Bereichen der präventiven und therapeutischen Impfstoffe konzipiert.
Under the terms of the agreement, PVT is eligible to receive an upfront payment, development, regulatoryand commercial milestone payments, as well as royalties on future product sales.
Ralf Amann, CEO of PVT, said, “We are pleased to partner with Boehringer on the development of newcancer immunotherapy approaches based on our ORFV platform. Having successfully advanced theplatform from preclinical research through GMP manufacturing and Phase I/IIa clinical evaluation ininfectious diseases, we are excited to further explore its potential in oncology with a partner that brings deepscientific and development expertise.”
“We are committed to developing differentiated new treatment options with the potential to have anunprecedented impact for people living with cancer, and this agreement adds another promising approach tothat effort” said Mark Petronczki, Head of Oncology Research at Boehringer Ingelheim. “We look forward to incorporating the ORFV platform into our work to build the next-generation of cancer vaccines andcombination treatments for patients.”
Boehringer Ingelheim intends to evaluate the platform both as a standalone cancer vaccine approach and incombination with assets across its oncology pipeline.
The agreement supports PVT´s strategy of advancing the ORFV platform through partnerships that can fullyexplore its scientific and therapeutic potential for oncology applications that require payload flexibility,scalable design, and the ability to support broad patient applicability through off-the-shelf developmentapproaches. Beyond this oncology partnership, PVT continues to pursue the broader potential of the ORFVplatform in infectious diseases and other vaccine applications.
